Brokerages Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Target Price at $17.89

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $17.89.

ATEC has been the subject of a number of research reports. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th.

Alphatec Price Performance

Shares of NASDAQ:ATEC opened at $12.42 on Wednesday. The business has a 50 day moving average price of $11.29 and a 200 day moving average price of $10.63. Alphatec has a twelve month low of $4.88 and a twelve month high of $13.14. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -9.70 and a beta of 1.06. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the previous year, the company earned ($0.34) EPS. Alphatec’s revenue for the quarter was up 22.2% compared to the same quarter last year. Research analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Insider Transactions at Alphatec

In other Alphatec news, COO Scott Lish sold 12,000 shares of Alphatec stock in a transaction on Monday, May 5th. The stock was sold at an average price of $12.12, for a total value of $145,440.00. Following the completion of the transaction, the chief operating officer now owns 826,251 shares in the company, valued at approximately $10,014,162.12. The trade was a 1.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total value of $135,032.24. Following the completion of the transaction, the chief executive officer now owns 5,857,603 shares of the company’s stock, valued at approximately $62,324,895.92. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,798 shares of company stock valued at $1,365,665. Corporate insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Several institutional investors have recently bought and sold shares of ATEC. R Squared Ltd bought a new position in Alphatec in the 4th quarter valued at $29,000. Comerica Bank raised its position in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 4,234 shares during the last quarter. Quarry LP raised its position in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after acquiring an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC bought a new stake in shares of Alphatec during the fourth quarter worth $50,000. Institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.